drugset / Trial / NCT05098080
Hutrukin to Analyze Safety and PK in Healthy Volunteers
RandomizedSequentialOpen-labelTreatment
Summary
The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
Timeline
- Start
- 2023-04-10
- Primary completion
- 2023-10-24
- Completion
- 2024-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hutrukin | Unknown | 1000 mg | Intravenous |
| Comparator | Hutrukin | Unknown | 3000 mg | Intravenous |
| Comparator | Hutrukin | Unknown | 5000 mg | Intravenous |
Indications
No indication recorded.